Impact of mass testing during an epidemic rebound of SARS-CoV-2: a modelling study using the example of France.


Journal

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
ISSN: 1560-7917
Titre abrégé: Euro Surveill
Pays: Sweden
ID NLM: 100887452

Informations de publication

Date de publication:
01 2021
Historique:
entrez: 8 1 2021
pubmed: 9 1 2021
medline: 26 1 2021
Statut: ppublish

Résumé

We used a mathematical model to evaluate the impact of mass testing in the control of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Under optimistic assumptions, one round of mass testing may reduce daily infections by up to 20-30%. Consequently, very frequent testing would be required to control a quickly growing epidemic if other control measures were to be relaxed. Mass testing is most relevant when epidemic growth remains limited through a combination of interventions.

Identifiants

pubmed: 33413741
doi: 10.2807/1560-7917.ES.2020.26.1.2001978
pmc: PMC7791601
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Paolo Bosetti (P)

Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, UMR2000, CNRS, Paris, France.

Cécile Tran Kiem (CT)

Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, UMR2000, CNRS, Paris, France.
Collège Doctoral, Sorbonne Université, Paris, France.

Yazdan Yazdanpanah (Y)

Infections Antimicrobials Modelling Evolution (IAME) UMR 1137, University of Paris, Paris, France.

Arnaud Fontanet (A)

Emerging Diseases Epidemiology Unit, Institut Pasteur, Paris, France.
PACRI Unit, Conservatoire National des Arts et Métiers, Paris, France.

Bruno Lina (B)

National Reference Center for Respiratory Viruses, Department of Virology, Infective Agents Institute, North Hospital Network, Lyon, France.
Virpath Laboratory, International Center of Research in Infectiology, INSERM U1111, CNRS-UMR 5308, École Normale Supérieure de Lyon, Université Claude Bernard Lyon, Lyon University, Lyon, France.

Vittoria Colizza (V)

INSERM, Sorbonne Université, Pierre Louis Institute of Epidemiology and Public Health, Paris, France.

Simon Cauchemez (S)

Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, UMR2000, CNRS, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH